BCYC Bicycle Therapeutics Plc - ADR

$BCYC Two and a half YEARS of non-transparency, non-communication, delays and cancellations of timelines, and not even a single scrap of good news takes quite the toll on a share price!

$BCYC Aggressively rejecting Friday's breakdown. Hinting at bottom possibly being reached

$BCYC Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.15 up 82.35% YoY • Reported revenue of $34.06M up 190.37% YoY • Bicycle Therapeutics reported cash and cash equivalents of $469.9M as of September 30, 2026, with expected cash runway into 2030, as stated in quarterly results.

$BCYC Watching this one closely. I’d love to start building a position here soon, the valuation looks severely disconnected from the underlying potential.

$BCYC Also, somewhat hidden in today's report, is mention that Bayer fully terminated their collaboration with Bicycle in July. That means that all 3 of Bicycle's BRC partnerships have been terminated by the partners (Bayer, Novartis, Genentech/Roche) in the past year or so.

$BCYC (NP) -$300M EV, deprioritized Nectin-4 in urothelial (the right move given high bar set by competition) Future= Epha2 in pancreatic and first Bicycle RadioConjugate entering the clinic 2H 27 (an exciting space, even if very early) Collaboration revenue tripled to $34M

$BCYC Hopefully this is the start of something very meaningful for us. I wonder what is in the works?